224 filings
Page 5 of 12
8-K
svhg5eok9r
26 Apr 21
Other Events
5:18pm
8-K
lvlz3728h0
5 Mar 21
Amendments to Articles of Incorporation or Bylaws
4:43pm
8-K
jh0vvz
12 Feb 21
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
4:05pm
8-K
g0udc1x6e dlswi6u
2 Feb 21
Departure of Directors or Certain Officers
5:13pm
8-K
buiavuyp1a2 z43pk
6 Jan 21
Other Events
4:05pm
8-K
vzyr9ee 0gysc
22 Dec 20
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
4:17pm
8-K
q4f7z wo4xzvem
1 Dec 20
Other Events
4:24pm
8-K
zc8o654aujv49hpzdicr
16 Nov 20
VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress
12:00am
8-K
mmk f4fo1mi
13 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:06pm
8-K
8yrm po6jgj6j
18 Sep 20
2020 Virtual Annual Meeting of Stockholders
9:14am
8-K
oqd2 trji7tjuaz
14 Aug 20
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
5:24pm
8-K
g5wj0wp7v38sen8
5 Aug 20
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
9:56pm
8-K
ohj990ch
24 Jul 20
Regulation FD Disclosure
6:03am
8-K
dps8iq5p03 uee58ea
30 Jun 20
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
4:16pm
8-K
ynhjnsh5
26 Jun 20
Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets
5:27pm
8-K
0p93d 6dk
1 Jun 20
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
4:53pm
8-K
220gs
18 May 20
The Proposed Phase 2A Open-label Study will be Conducted in New York City
5:15pm
8-K
2e4yi68qny14
28 Apr 20
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
4:32pm
8-K
o7ctq7 uv
27 Apr 20
Entry into a Material Definitive Agreement
5:16pm
8-K
kkrwe
3 Apr 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm